Mannkind's share price has started a definite uptrend.
The C.E.O., billionaire Al Mann, recently stated that Mannkind was in talks with multiple potential partners.
A recent rumor from flyonthewall.com stated that Lilly was readying a $12.50/share offer for Mannkind.
Big pharma is faced with losing over $100 billion in revenues over the next three years with drugs going "off-patent". Mannkind is one of the few companies with a potential blockbuster drug in late stage development that is a realistic partner or buyout target for a major drug company.
With almost 25,000,000 shares short (about 40% of the float) news of a partnership could take the share price to the $15.00 range.
Due diligence but do check it out before it gaps higher.